However, since the initial Federal Drug Administration (FDA) approval of IFN-β, there has been a trend for breast cancer noted in a study of the British Columbia MS database, evaluating a cohort of 5146 relapsing-onset MS patients and 48,705 person-years of follow-up, that did not reach statistical significance (39). This evidence concerns the gene IFNB1 and breast cancer.